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Abstract
Adherence to highly active antiretroviral therapy (HAART) is the mainstay of the strategy in reducing morbidity and mortality 
of HIV-infected children. Different primary studies were conducted in Ethiopia. Thus, we aimed to conduct a meta-analysis 
of the national prevalence of optimal adherence to HAART in children. In addition, associated factors of HAART adherence 
were reviewed. A weighted inverse variance random-effects model was applied. The 88.7 and 93.7% of children were adher-
ing to HAART at 07 and 03 days prior to an interview respectively. The subgroup analysis showed that HAART adherence 
was 93.4% in Amhara, 90.1% in Addis Ababa and 87.3% in Tigray at 07 days prior to an interview. Our study suggests that, 
within short window reported time, adherence to HAART in Ethiopian children may be in a good progress. Emphasis on spe-
cific adherence interventions need further based on individual predictors to improve overall HAART adherence of children.
Keywords Adherence · Antiretroviral therapy · Children · Highly active · HIV · Medication · Meta-analysis · Ethiopia
Resumen
La adherencia a la terapia antirretroviral altamente activa (HAART) es el pilar de la estrategia de reducción de la morbilidad 
y la mortalidad de los niños infectados con el VIH. Diferentes estudios primarios fueron realizados en Etiopía. Por lo tanto, 
decidimos realizar un meta-análisis de la prevalencia nacional de excelente adherencia al TARGA en los niños. Además, 
los factores asociados de cumplimiento del TARGA fueron revisados. Inverso de la varianza ponderada de un modelo de 
efectos aleatorios se aplicó. El 88,7% y el 93,7% de los niños estaban adheridos al TARGA en 07 y 03 días antes de una 
entrevista, respectivamente. El análisis de subgrupos demostró que el cumplimiento del TARGA fue de 93,4% en Amhara, 
90,1% en Addis Abeba y 87,3% en Tigray en 07 días previos a la entrevista. Nuestro estudio sugiere que, dentro de breve 
tiempo informado de la ventana, la adherencia al TARGA en niños etíopes pueden tener un buen progreso. Énfasis en la 
adherencia al tratamiento, las intervenciones específicas deben seguir basándose en predictores individuales para mejorar 
el nivel general de cumplimiento del TARGA de niños.
Keywords Adherencia · Terapia antirretroviral altamente activa · Niños · VIH · Medicamentos · Meta-análisis · Etiopía
Background
According to 2017 World Health Organization’s (WHO) 
report, 36.7 million people were living with HIV/
AIDS (Human Immunodeficiency Virus/Acquired 
Immunodeficiency Syndrome) around the globe, of which 
2.1 million were children less than 15 years of age [1]. It is 
estimated 1.1% of the Ethiopian population living with HIV, 
of which 10% were children [2]. Access to highly active 
antiretroviral therapy (HAART) in low- and middle-income 
countries has expanded dramatically [3]. Subsequently, 
HAART coverage is increasing; and nearly 20.9 million peo-
ple were taking HAART in June 2017. Among children liv-
ing with HIV, 43% accessed HAART [1]. In Ethiopia, 61% 
of adults aged 15 years and older living with HIV had access 
to HAART, but just 33% of children aged below 15 years 
had access [2].
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HIV-related morbidity and mortality occurred signifi-
cantly even in the presence of HAART [4–7] although 
HAART plays a significant role in improving the life of 
HIV-positive patients [8]. Adherence to drugs is critical 
in determining the efficacy and durability of HAART regi-
mens [9, 10]. For optimal therapeutic effect, at least ≥ 95% 
HAART adherence has been suggested [11, 12], though the 
minimum value for optimal adherence is not well defined 
[13, 14]. Missing a prescribed regimen has a remarkable 
contribution to the emerging of treatment failure [15–17] 
and resistance to HIV/AIDS drugs [18, 19].
Adherence promoting-interventions are implementing 
in different parts of the world including Ethiopia. Nota-
bly, implementing interventions evaluation, home-based 
HAART [20], social support [21, 22], educational [23], 
daily observable treatment [24], and community-based 
HAART program [25] are considering the main strategies 
to increase optimal HAART adherence of HIV-infected 
children.
Although measuring of optimal adherence remains a chal-
lenge since there is no single method that is reliable [26, 27], 
the most frequently used measure of adherence in children 
is caregivers’ report. Accordingly, the prevalence of optimal 
adherence of children to HAART is 90.9% in South India 
[28], 77% in India [29], 77% in China [30], 42% in West 
Africa [31] and 76.1% in Nigeria [32].
Common barriers to HAART optimal adherence are 
categorized as socio-demographic, behavioral, clinical and 
health system related factors [28, 33, 34]. Among these fac-
tors, some of them are unfavorable school environment, pills 
burden of the HIV drug, treatment longevity, being unaware 
of HIV status, non-parental care, preference for traditional 
medicine and forgetfulness [35–38].
National [39, 40] and international [41–44] systematic 
review and meta-analysis have been conducted among the 
adult population. In Ethiopia, many studies [45–55] have 
been conducted on the prevalence of optimal adherence to 
HAART and its associated factors among HIV-infected chil-
dren. Discrepancies among studies in the same geographical 
area, across regions, at a similar and different time period, 
were reported. While the study by Dachew et al. [47.] esti-
mated a high rate of 96.8% HAART adherence, the study 
by Feyissa [54] showed a prevalence of 61.5%. Therefore, 
the national prevalence of optimal adherence to HAART 
and its contributing factors among HIV-infected children 
are poorly understood. Given the above gaps, the aim of the 
present study was to (i) estimate the national pooled preva-
lence of optimal adherence to HAART from the available 
literature of HIV-infected children in Ethiopia that maintain 
an intake of ≥ 95% of prescribed HAART and [4] systemati-
cally review the associated factors of HAART adherence in 
HIV-infected children. The finding of this study will provide 
information for clinicians, policy and decision makers.
Methods
Reporting
The Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) guideline was used to report the 
finding of this review [56] (Additional file research check-
list). The protocol of this systematic review and meta-anal-
ysis was registered in the Prospero database: (PROSPERO 
2017: CRD42018081755).
Databases and Search Strategy
A comprehensive search was carried out in PubMed, 
Google Scholar, Web of Science, Wiley Online Library and 
EMBASE electronic database up to 03 November 2017. The 
search focused on the studies with reported prevalence of 
optimal HAART adherence and/or at least one associated 
factor among Ethiopian children. The search further limited 
to articles published in English. The following terms and/or 
phrases were used: “ART”; “HAART”; “Antiretroviral ther-
apy”; “highly active antiretroviral therapy”; “adherence”, 
“poor adherence”; “good adherence”; “non-adherence”; 
“patient compliant”; “children”; “child”; “Pediatrics”; 
“infant”; “infants”; and “Ethiopia”. Search strings were 
implemented using “AND” and “OR” Boolean operators.
Inclusion and Exclusion Criteria
The studies were included if they met the following inclu-
sion criteria: [1] studies conducted on children < 15 years 
of age; [2] observational studies, including cross-sectional, 
cohort and case–control studies; [3] studies that reported 
prevalence of optimal adherence and/or at least one predic-
tor, which was adjusted to other factors; [4] the outcome 
was optimal adherence to HAART; [5] studies conducted in 
Ethiopia; [6] studies published in English language. Opti-
mal adherence to HAART among included studies in this 
meta-analysis was defined as according to caregiver report 
if children took ≥ 95% of the prescribed doses for 07 days 
[45–54] and 03 days [46, 47, 49, 50, 53, 55] prior to an 
interview. Qualitative studies and citations without full-text 
were excluded. Studies conducting on adherence to HAART 
prophylaxis like mother to child transmission prophylaxis 
were also excluded.
Study Selection and Quality Assessment
We used Endnote version 7 (Thomson Reuters, London) ref-
erence manager to remove duplicated studies. Two reviewers 
(AE and TD) independently screened the titles and abstracts 
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to consider the articles in the full-text review. Two investiga-
tors (AE and NT) assessed the quality of the studies using 
Joanna Brigg’s Institute quality appraisal criteria (JBI) [57]. 
The following items were used to appraise the selected stud-
ies: [1] inclusion criteria; [2] description of study subject 
and setting; [3] valid and reliable measurement of exposure; 
[4] objective and standard criteria used; [5] identification of 
confounder; [6] strategies to handle confounder; [7] outcome 
measurement; and [8] appropriate statistical analysis. The 
disagreement was solved by consensus. Studies got 50% and 
above of the quality scale were considered low risk.
Data Extraction
Two independent reviewers (AE and SE) extracted the 
data. The procedure was repeated whenever inconsistency 
occurred. Information about the first author and year of 
publication, study setting, study design, sample size, and 
prevalence and associated factors of optimal adherence to 
HAART were extracted. Assessment method for optimal 
adherence in all included studies was through caregiver 
report. Studies preferred times to report the prevalence of 
optimal adherence were 07 and/or 03 days prior to an inter-
view. All included studies didn’t consistently use both 03 
and 07 days prior to an interview. To answer the questions 
regarding [1] the prevalence of optimal adherence at 07 days 
prior to an interview and [2] the prevalence of optimal 
adherence at 03 days prior to an interview, we collected the 
data in the theme, in which studies reported the prevalence 
of optimal adherence at 07 days as one theme and studies 
reported the prevalence of optimal adherence at 03 days in 
the other theme.
Data Analysis
A weighted inverse variance random-effects model [58] was 
used to estimate the prevalence of optimal HAART adher-
ence at 07 and 03 days prior to an interview. The varia-
tion in the pooled estimates of the prevalence was adjusted 
through subgroup analysis according to the region, where 
the study conducted. Heterogeneity across the studies was 
assessed using  I2 statistic where 25, 50 and 75% representing 
low, moderate and high heterogeneity respectively [59]. A 
Funnel plot and Egger’s regression test were used to check 
publication bias [60]. A sensitivity analysis was conducted 
to check the stability of summary estimate. We used STATA 
version 14 (Stata Corp, 4905 Lake way Drive, College Sta-




In total, 332 potential studies were identified; 94 articles 
from PubMed, 102 articles from Google Scholar, 44 from 
EMBASE, 75 articles from Web of Science, and 17 articles 
through manual search. Figure 1 showed the results of the 
search and reasons of exclusion during the study selection 
Fig. 1  PRISMA flow diagram 
showed the results of the search 
and reasons for exclusion
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process. A total of 11 studies were included to assess the 
prevalence of optimal adherence to ART at 07 and 03 days 
prior to an interview.
Included studies were published between the years 2008 
and 2017. A cross-sectional study design was employed for 
all included studies. Three studies conducted in Amhara 
region [46, 47, 55], two in Oromia [52, 54], two in Tigray 
[50, 53], two in Addis Ababa [45, 48], one in Oromia and 
Addis Ababa [51] and one in Harare and Dire Dawa city 
[49]. Five studies reported the prevalence of optimal adher-
ence both at 07 days and 03 days prior to an interview [46, 
47, 49, 50, 53] whereas five studies reported only preva-
lence at 07 days prior to an interview [45, 48, 51, 52, 54]. 
One study reported the prevalence of optimal adherence at 
03 days prior to an interview [55]. Therefore, ten studies 
[45–54] reported the prevalence of optimal adherence at 
07 days and six studies [46, 47, 49, 50, 53, 55] at 03 days 
prior to an interview. A total of 2,864 HIV-infected chil-
dren were participated in the included studies. The minimum 
sample size was 120 observed in Oromia [52, 54] and the 
maximum 440 in Amhara region [46]. Table 1 presents the 
characteristics and outcomes of reviewed studies.
Quality of the Included Studies
All studies were assessed using JBI checklist for cross-sec-
tional studies. The assessment with JBI quality appraisal 
checklists indicated that none of the included studies were 
of poor in quality and excluded from the meta-analysis 
(Table 1).
Meta‑analysis
Prevalence of Adherence 07 Days Prior to Interview
The prevalence of optimal HAART adherence among 
HIV-positive children at 07 days prior to interview ranges 
from 61.5% (95% confidence interval (CI) 52.8–70.2) in 
Oromia [54] to 96.8% (95%CI 94.9–98.7) [49] in Amhara 
region. The estimated national pooled prevalence of optimal 
HAART adherence was 88.8% (95% Confidence Interval 
(CI) 85.1–92.5,  I2 = 92.6%; p value < 0.001) (Fig. 2).
Prevalence of Adherence 03 Days Prior to Interview
The prevalence at 03 days prior to an interview ranges from 
80.9% (95%CI 75.5–86.3) [55] in Amhara to 99.0% (95%CI 
97.9–100.1) Harare and Dire Dawa [49]. The national pooled 
prevalence of optimal HAART adherence at 03 days prior 
to an interview was 93.7% (95% CI 90.6–96.8,  I2 = 93.0%; 
p value < 0.001) (Fig. 3).
Subgroup Analysis
Subgroup analysis based on geographical area (study set-
ting) was estimated. The prevalence at 03 days prior to an 
interview was 92.7% in Amhara and 93.9% in Harare and 
Dire Dawa (Additional file Fig. 1). The prevalence at 07 days 
prior to an interview was 90.1% in Addis Ababa, 93.4% in 
Amhara, 87.3% in Tigray, 73.0% in Oromia and 95.1% in 
others region (Additional file Fig. 2).
Sensitivity Analysis
We did the sensitivity analysis of adherence to HAART by 
applying a random effects model (Table 2). Excluded studies 
Table 1  General characteristics and outcomes of the included studies (n = 11)
Author/year Study area Study design Sample size Prevalence at 
07 days prior to 
interview
Prevalence at 
03 days prior to 
interview
Quality
Biresaw S et al./2013 Addis Ababa Cross-sectional 210 93.3 _ Low risk
Arage G et al./2014 Amhara Cross-sectional 440 89.8 95.9 Low risk
Dachew BA et al./2014 Amhara Cross-sectional 342 96.8 98.7 Low risk
Biadgilign S.et al./2008 Addis Ababa Cross-sectional 390 86.9 _ Low risk
Zegeye S, Sendo EG/2015 Harare and Dire dawa Cross-sectional 313 97 99 Low risk
Eticha T, Berhan L/2014 Tigray Cross-sectional 193 83.4 89.1 Low risk
Biru M et al./2017 Oromia and Addis Ababa Cross-sectional 306 92.8 _ Low risk
Alemu K et al./2014 Oromia Cross-sectional 120 84.2 _ Low risk
Gultie T et al./2014 Tigray Cross-sectional 226 90.7 92.9 Low risk
Feyissa A/2016 Oromia Cross-sectional 120 61.5 _ Low risk
Azmeraw D, Wasie B/2012 Amhara Cross-sectional 204 _ 80.9 Low risk
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with a low number of participants resulted in a slight differ-
ence in the prevalence of optimal HAART adherence.
Publication Bias
We visually examined signs of asymmetry using Fun-
nel plots to assess publication bias (Fig.  4). Moreover, 
more objectively, Egger’s regression test resulted in a p 
value = 0.23 and p value = 0.26, 07 and 03 days prior to an 
interview respectively, which indicates the absence of pub-
lication bias in both cases.
Factors Associated with Adherence to HAART 
This systematic review identified eleven studies that reported 
factors associated with HAART adherence as categorized 
into four themes related to (1) children and caregiver socio-
demographic, (2) clinical and medication, (3) behavioral, 
and (4) health care system.
Children and Caregiver Demographic‑Related Factors
Being in the age group 5–9 years [adjusted odds ratio 
(AOR) = 0.42 (95% CI 0.36, 0.54)] and 10–15  years 
[AOR = 0.37 (95%CI 0.31, 0.46)] were less likely to have 
optimal adherence as compared to 0–5 years old children 
[47]. In contrary, one study showed that being in the age 
group below 5 years [AOR = 1.4 (95%CI 1.2, 3.9)] was 
more likely to adhere as compared to > 10 years age chil-
dren [53]. Children with male caregiver [AOR = 2.10, 
95% CI (1.01, 7.2)] was positively associated with 
HAART adherence [53]. Other factors associated with 
suboptimal adherence across studies including being 
female (AOR = 3.9) [52], children with the age group 
of 25–34  years (AOR = 22.3 (95%CI 4.3, 114.3) and 
35–44 years caregiver [AOR = 7.1 (95%CI 1.6, 30.9)] as 
compared to those with > 44 years age group [50]. Another 
study revealed, children with caregivers who had second-
ary or above educational status [AOR = 0.59 (95%CI 0.21, 
0.83)] were less likely adhere with HAART. Children with 
unmarried [AOR = 15.2 (95%CI 3.4, 68.4)] and married 
caregiver [AOR = 3.5 (95%CI 1.2, 10.1)] [50] were more 
likely to have optimal HAART adherence than those with a 
divorced/separated caregiver. One study also revealed that 
children with married (AOR = 7.8 (95%CI 2.1, 29.1) and 
widowed/divorced caregiver (AOR = 7.1 (95%CI 2.0, 25.5) 
were more likely to have optimal adherence as compared 
to those with single caregiver [45].
Fig. 2  Pooled estimates of the prevalence of optimal adherence to 
ART among HIV-infected children 07 days prior to the interview. The 
midpoint and the length of each segment indicated prevalence and a 
95% CI whereas the diamond shape showed the combined prevalence 
of all studies
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Clinical and Medication Related Factors
Children on WHO stage II (AOR = 0.128) and IV 
(AOR = 0.055) were less likely to optimal HAART adher-
ence as compared to WHO stage I [52]. Other study 
explained that children on WHO stage III and IV [AOR = 3.2 
(95%CI 1.2, 8.4)] were less likely to have optimal HAART 
adherence as compared to WHO stage I and II [45]. Chil-
dren who had CD4 count ≥ 500 (AOR = 1.9 (95%CI 1.3, 3.9) 
were more likely adhere to HAART as compared to < 500 
Fig. 3  Pooled estimates of optimal adherence of children to ART 03 days prior to an interview. The midpoint and the length of each segment 
indicated prevalence and a 95% CI whereas the diamond shape showed the combined prevalence of all studies
Table 2  Sensitivity analysis 
07 and 03 days prior to an 
interview
Study omitted Prevalence of optimal adherence 
(95%CI) 07 days prior to an interview
Prevalence of optimal adher-
ence (95%CI) 03 days prior to an 
interview
Biressaw S. et al./2013 88.2 (84.0, 92.3) _
Arage G et al./2014 88.6 (84.5, 92.7) 93.0 (89.2, 96.9)
Dachew BA et al./2014 87.7 (83.5, 91.9) 92.2 (87.6, 96.7)
Biadgilign S et al./2008 89.0 (85.1, 92.9) _
Zegeye S, sendo EG/2015 87.7 (83.5, 91.8) 92.1 (87.7, 96.5)
Eticha T, Berhan L/2014 89.4 (85.6, 93.2) 94.6 (91.5, 97.7)
Biru M et al./2017 88.2 (84.0, 92.4) _
Alemu K et al./2014 89.2 (85.4, 93.1) _
Gultie T et al./2014 88.5 (84.4, 92.6) 93.9 (90.5, 97.3)
Feyissa A/2016 91.0 (88.0, 94.0) _
Azmeraw D, Wasie B/2012 _ 95.9 (93.5, 98.3)
Combined 88.8 (85.1, 92.5) 93.7 (90.6, 96.8)
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[46]. Regarding types of HAART, children who were on 
first line HAART drugs [AOR = 2.9 (95%CI 1.5, 3.7)] were 
more likely adhere to HAART [53]. Children who were on 
4b (d4T/3TC/EFV) ART [AOR = 0.1 (95%CI 0.02, 0.53)] 
were less likely adhere to HAART as compared to those 
who were on 4a (d4T/3TC/NVP) [45]. Whereas, children 
received LPV/r or ABC [AOR = 12.3 (95%CI 3.3, 46.7)] 
were less likely adhere to HAART as compared to those 
children received 4a/4b or 4c/1c/4d [51]. Children who took 
Cotrimoxazole besides HAART [AOR = 3.65 (95%CI 1.2, 
10.7)] were more likely to have optimal HAART adherence 
[48]. Children whose caregivers were not undergoing HIV 
care and treatment themselves were less likely to have opti-
mal HAART adherence (AOR = 0.2, 95% CI 0.04, 0.7) [51].
Behavior Related Factors
Among the reviewed studies, three were showed children 
who were not aware of their HIV sero-status were more 
likely adhere to HAART as evidenced by [AOR = 3.5 
(95%CI 2.1, 6.8)] [46], [AOR = 2.4 (95%CI 1.1, 5.1)] [45], 
[AOR = 2.5(95%CI 1.2, 5.2)] [48]. Aside from another 
one study, children aware of their HIV status [AOR = 0.27 
(95CI 0.24, 0.32)] were less likely to have optimal HAART 
adherence [47]. Two studies showed that children with sub-
stance user caregivers [AOR = 2.2 (95%CI 1.3, 5.4)] [46], 
(OR = 0.31, 95%CI 0.10, 0.93) [55] were less likely to 
HAART adherence. Children whose caregivers did not use 
a medication reminder (AOR = 5.2, 95% CI 2.2, 12.2) were 
more likely to HAART non-adherence [51].
Children with caregivers who had good knowledge about 
HAART (AOR = 4.7 (95%CI 3.7, 5.6) [47], [AOR = 2.7 
(95%CI 1.8, 7.1)] [46], [AOR = 7.31(95%CI 1.7, 6.1)] [49] 
was additional factors found in the review to be promoting 
factors of optimal HAART adherence.
Health Care System Related Factors
Children living in < 10 K.M far distance from the health 
facility [AOR = 2.3 (95%CI 1.9, 4.6)] were more likely to 
have optimal HAART adherence as compared to > 10 KM 
[46]. Children who had ever received any nutritional sup-
port from the clinic were 66.3% less likely to adhere with 
HAART than those who did not get the nutritional support 
[AOR = 0.34 (95% CI 0.14, 0.79)] [48].
Discussion
This systematic review and meta-analysis was conducted to 
estimate the national pooled prevalence of optimal HAART 
adherence among HIV-infected children in Ethiopia. 
Fig. 4  Graph a stands 07 days and graph b 03 days prior to an interview
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Besides, significantly associated factors of HAART adher-
ence were systematically reviewed. Accordingly, the 
national pooled prevalence of optimal HAART adherence 
at 07 and 03 days prior to an interview was 88.8 and 93.2% 
respectively.
The result of this meta-analysis was comparable to a 
study conducted in South India (90.9%) [28]. However, it 
was higher than a globally meta-analyzed report (62%) [41], 
China (77.6%) [30], Africa (77%) [61], India (70%) [29], 
West Africa (42%) [31]. These discrepancies might be due to 
the difference in socio-demographic characteristics, health-
care systems, the adherence report method and/or date, study 
population and study design.
The subgroup analysis showed that the adherence of 
children to HAART in Amhara region (93.4%) was consist-
ent to Addis Ababa (90.1%). In contrast, it was higher than 
Oromia region (73.04%) and Tigray region (87.3%). This 
variation might be due to the difference in health care sys-
tem and clinical setting, attitude and awareness of caregiv-
ers about HAART. Additionally, beliefs about the benefit of 
HAART, religious practices and use of traditional medicine 
might have an influence on optimal adherence in Oromia 
region [62]. However, the prevalence of optimal adherence 
to HAART 03 days prior to an interview was comparable 
between regions. This might be due to the fact that as the 
duration of taking drugs increased, the probability of miss-
ing drugs would increase due to different reasons.
The children and caregiver, and clinical and medication, 
behavioral, and health care system related variables were 
contribute on HAART adherence of children Ethiopia. In 
agreement with our review, varieties of studies both in devel-
oped and developing countries identified such like variables 
[63–67].
Our systematic review showed that age [47] and sex of 
children [52], caregivers’ age [50] and marital status [45, 
50] were associated factors of HAART adherence. Older 
children were less likely to have HAART adherence. As chil-
dren age increased, many responsibilities are given so that 
children couldn’t successfully handle the treatment regimen. 
Female children were less likely to adhere to HAART. This 
might be due to the influence of gender roles, in which they 
could forget taking of HAART pills per the scheduled. Chil-
dren whose caregivers were married were more adhere to 
HAART. Married caregivers might have support from their 
husband in providing respectful and compassionate care.
Regarding clinical related factors, WHO clinical stage 
III and IV [45], use of first-line HAART drugs [53], and use 
of Cotrimoxazole [45] were positively influencing HAART 
adherence. Those children with advanced opportunistic 
infections might become more inspire to have well health 
and this might give energy to take the prescribed HAART 
appropriately. First-line HAART relatively has a less adverse 
effect than second-line HAART. Moreover, the level of 
adherence of children to first-line HAART could predict 
the probability of adherence to second-line HAART [68]. If 
children unfitted to first line HAART due to drug resistance 
and/or treatment failure, the probability they adhere with 
HAART could be less likely. The client might have enough 
information about the use of Cotrimoxazole prophylaxis so 
that they took the medication per the scheduled. Moreover, 
Cotrimoxazole prevent and control the occurrence and pro-
gression opportunistic infection that might help the child 
to be well adhered to HAART. On the other hand, protease 
inhibitors types of HAART [51] and caregivers not caring 
themselves [51] were significantly impair HAART adher-
ence of children.
Our finding highlighted the importance of behavioral 
factors in HAART optimal adherence. Knowledge of car-
egiver [45, 46, 48, 49] was the most frequently reported 
factors positively associated with optimal adherence. Chil-
dren whose caregiver was substance user [46, 55] and those 
didn’t use medication reminder [51] were negatively influ-
encing HAART adherence. It is known that the use of alarm-
ing materials could remind the caregiver or children who 
forget the time of taking HAART so that they administer 
their medication as well. The association between optimal 
HAART adherence and disclosure of HIV status to chil-
dren so far resulted differently [45–48]. This might be due 
to the finding relies on the caregiver report, which might not 
be accurately ascertained formal and unplanned disclosure 
status. In Ethiopia, by considering child’s psychological 
and social developmental status, sero-disclosure to children 
begins to be formal when they reach the age of 6 years and 
above. However, most of the studies included in this review 
wouldn’t consider these issues. Therefore, the finding from 
this review might provide an implication for further large 
scale study that concern about HIV disclosure status of chil-
dren and HAART adherence in Ethiopia.
Our review found that proximity to the health care facil-
ity [46], and nutritional support [48] were promoting fac-
tors of optimal HAART adherence. As far as distance from 
health center increased, the probability of getting frequent 
information about the importance of HIV medication would 
decrease, which leads to a missed HAART doses. Further-
more, lack of vehicles and long distance might have a con-
tribution to miss the appointment of HAART users. In our 
review, one study found that those children who received 
nutritional support [48] were more likely to have optimal 
HAART adherence. Nutritional support like plumy nut could 
help to maximize the health of children which aid to benefit 
the uses of HAART. Another studies out of Ethiopian set-
tings also showed cost and access to transportation, lack 
of understanding of the benefit of HIV drugs, economic 
problems in the household, and lack of nutritional support 
have been associated with suboptimal HAART adherence 
[69–71].
AIDS and Behavior 
1 3
Patient and HIV-care program monitoring, establish and 
strength linkages with other facility-based systems like TB 
monitoring, HIV care and HAART, HIV testing and coun-
seling, perinatal care and electronic systems need to be 
implemented in every segments’ of Ethiopian settings. In 
addition, an improvement of healthcare settings, behavioral 
support, economic strengthening and home-based care indi-
cated more emphasis.
Strength and Limitation
This is the first systematic review and meta-analysis con-
ducted in Ethiopia to show the national estimates of the 
prevalence of optimal adherence among HIV-infected chil-
dren. There was no publication bias found in this meta-anal-
ysis as objectively explained by Egger’s regression test. It 
helps to increase the certainty of this evidence on decision 
making and resource utilization because the unbiased evi-
dence is generated.
The reported past-three and 7 days adherence consider 
a relatively short window of period and may not represent 
adherence levels in the years. Since limited studies were 
conducted in some regions of the country, the current find-
ings may not be nationally representative. High heterogene-
ity was found, as well as the scarcity of available factors to 
explain this variability only study setting was considered in 
the subgroup analysis. Another limitation is that all of the 
studies included in this systematic review and meta-analysis 
applied a cross-sectional design, making it difficult to deter-
mine the causal relationship between prevalence of optimal 
adherence and factors. Method of assessment of studies 
was care-giver report, which could overestimate adherence 
because of a desire to please the treatment provider and 
prevent criticism. Additionally, care-giver report could be 
vulnerable to recall-bias.
Conclusion and Future Directions
Our study suggests that, within short window reported time, 
adherence to HAART in Ethiopian children may be in a 
good progress. This review revealed demographic charac-
ters, clinical and medication, behavioral and health care 
system related factors have been contributed on children 
HAART adherence status. The lowest prevalence of optimal 
adherence observed in Oromia region, Ethiopia. Emphasis 
on specific adherence interventions need further based on 
individual predictors to improve overall HAART adherence 
of children in Ethiopia.
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